Related Experiment Videos

Adherence to interferon-beta treatment and results of therapy switching

Marinella Clerico1, Pierangelo Barbero, Giulia Contessa

  • 1Divisione Universitaria di Neurologia, Ospedale Clinicizzato San Luigi Gonzaga, Dipartimento di Scienze Cliniche e Biologiche, Universita' di Torino, Torino, Italy. marinellaclerico@libero.it

Journal of the Neurological Sciences
|March 23, 2007
PubMed

Insights

Identifying early indicators of treatment response in multiple sclerosis (MS) is crucial. A single active MRI scan within six months of interferon-beta treatment can predict future disease activity in MS patients.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Long-term adherence to multiple sclerosis (MS) therapy is challenging, with many patients discontinuing treatment within the first year due to perceived lack of efficacy.
  • Parenteral administration of immunomodulatory drugs is the standard treatment for MS, requiring long-term commitment.

Purpose of the Study:

  • To identify an early indicator of treatment response in multiple sclerosis patients.
  • To enable the early identification of patients with poor response to interferon-beta (IFNbeta) therapy.

Main Methods:

  • The OPTIMS (OPTimization of Interferon dose for MS study) was a multicenter trial involving 216 patients across 24 Italian MS centers.
  • Patients' treatment response was monitored, with a focus on identifying predictors of disease activity.
  • Magnetic resonance imaging (MRI) scans were used to assess disease activity.

Main Results:

  • A single active MRI scan during the initial 6 months of IFNbeta treatment demonstrated a significant positive predictability (59%) for clinical disease activity over a subsequent 2-year follow-up.
  • This finding suggests that early MRI findings can help identify patients who may not respond optimally to treatment.

Conclusions:

  • Early identification of treatment response indicators is vital for optimizing multiple sclerosis management.
  • Utilizing early MRI scans may allow for timely adjustments in therapy for non-responding patients, potentially improving long-term outcomes.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...